Key result
Colchicine post-MI fails to reduce all-cause mortality versus placebo but increases diarrhea risk.
Why the study?
Colchicine has emerged as a potential anti-inflammatory treatment option following MI, warranting an assessment of its efficacy and safety in this setting.
Does oral colchicine reduce all-cause mortality and cardiac death in patients with acute myocardial infarction?
Meta-Analysis (n=13,834)
Does oral colchicine reduce all-cause mortality and cardiac death in patients with acute myocardial infarction?
Relative Risk: 0.93 (95% CI 0.78–1.11)
p-value: p=0.44
In patients with acute myocardial infarction, colchicine does not significantly reduce mortality or major cardiovascular events but increases the risk of diarrhea.
Colchicine should not be used routinely post-MI to reduce mortality; confirms lack of survival benefit despite anti-inflammatory rationale.
Colchicine is an anti-inflammatory drug that has emerged as a potential treatment option following myocardial infarction (MI). This meta-analysis assesses the efficacy and safety of colchicine in patients following an MI. A comprehensive literature search was performed using the Cochrane Library, ClinicalTrials.gov, Embase, and MEDLINE, covering studies from their inception to December 2025. RevMan was used to perform a random-effects meta-analysis, and forest plots were used to visualize pooled estimates. The Mantel-Haenszel method was applied to analyze dichotomous outcomes. Nine randomized control trials (RCTs) were included in this meta-analysis, including 13,834 patients. The analysis revealed that there was no statistically significant difference between colchicine and placebo groups in all-cause mortality [relative risk (RR)=0.93, confidence interval (CI)=0.78-1.11], cardiac death (RR=0.95, CI=0.73-1.22), MI (RR=0.82, CI=0.67-1.00), stroke (RR=0.64, CI=0.26-1.58), adverse events (RR=1.01, CI=0.85-1.21), serious adverse events (RR=0.96, CI=0.87-1.05), serious gastrointestinal adverse events (RR=1.35, CI=0.94-1.95), and serious infections (RR=1.00, CI=0.62-1.62). However, there was an increased risk of diarrhea in people with colchicine compared to the placebo (RR=2.12, CI=1.35-3.32). This meta-analysis demonstrates that colchicine following an MI does not have a significant impact on cardiovascular events or major adverse events other than an increased risk of diarrhea. There is a need for more comprehensive RCTs with longer follow-up times to fully comprehend the potential cardiovascular benefits of colchicine.
No takes yet. Share an insight, caveat, or question.
Saleem et al. (2026) conducted a meta-analysis in myocardial infarction (n=13,834). Colchicine vs. Placebo was evaluated on all-cause mortality (RR 0.93, 95% CI 0.78-1.11, p=0.44). Colchicine administration following a myocardial infarction did not significantly reduce all-cause mortality (RR 0.93) compared to placebo, but increased the risk of diarrhea.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: